Potent growth-inhibitory effect of a dual cancer-specific oncolytic adenovirus expressing apoptin on prostate carcinoma

Zhang,Muchun; Wang,Jinhui; Li,Chang; Hu,Ningning; Wang,Kai; Ji,Huifan; He,Dongyun; Quan,Chengshi; Li,Xiao; Jin,Ningyi; Li,Yulin

doi:10.3892/ijo.2013.1783

Potent growth-inhibitory effect of a dual cancer-specific oncolytic adenovirus expressing apoptin on prostate carcinoma

Authors:
- Muchun Zhang
- Jinhui Wang
- Chang Li
- Ningning Hu
- Kai Wang
- Huifan Ji
- Dongyun He
- Chengshi Quan
- Xiao Li
- Ningyi Jin
- Yulin Li
View Affiliations

Affiliations: Department of Urology, China-Japan Union Hospital of Jilin University, Changchun 130031, P.R. China, Institute of Military Veterinary, Academy of Military Medical Sciences of PLA, Changchun 130122, P.R. China, The Key Laboratory of Pathobiology, Ministry of Education, Changchun 130021, P.R. China
Published online on: January 21, 2013 https://doi.org/10.3892/ijo.2013.1783
Pages: 1052-1060

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Apoptin is a chicken anemia virus-derived, p53-independent, bcl-2-insensitive apoptotic protein with the ability to specifically induce apoptosis in various human tumor cells, but not in normal cells. To explore the use of apoptin in tumor gene therapy, we assessed a recombinant adenovirus expressing the apoptin protein (Ad-hTERTp-E1a-Apoptin) in order to determine its lethal and growth-inhibitory effects on PC-3 and RM-1 cells in vitro and its antitumor effect on solid tumors in vivo. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), acridine orange (AO)/ethidium bromide (EB), 4'-6-diamidino-2-phenylindole (DAPI), and Annexin V assays showed that Ad-hTERTp-E1a-Apoptin inhibited the proliferation of PC-3 and RM-1 cells in vitro by inducing apoptosis of prostate cancer cells, and that this inhibitory effect was dose and time-dependent. In the animal models, Ad-hTERTp-E1a-Apoptin significantly inhibited tumor growth and extended the lifespan of animals. Experimental results indicate that Ad-hTERTp-E1a-Apoptin has a potential application in tumor gene therapy.

View Figures

View References

1	Damber JE and Aus G: Prostate cancer. Lancet. 371:1710–1721. 2008. View Article : Google Scholar : PubMed/NCBI
2	Burton AJ, Tilling KM, Holly JM, Hamdy FC, Rowlands MA, Donovan JL and Martin RM: Metabolic imbalance and prostate cancer progression. Int J Mol Epidemiol Genet. 1:248–271. 2010.PubMed/NCBI
3	Di Lorenzo G and De Placido S: Hormone refractory prostate cancer (HRPC): present and future approaches of therapy. Int J Immunopathol Pharmacol. 19:11–34. 2006.PubMed/NCBI
4	Dash R, Azab B, Shen XN, Sokhi UK, Sarkar S, Su ZZ, Wang XY, Claudio PP, Dent P, Dmitriev IP, Curiel DT, Grant S, Sarkar D and Fisher PB: Developing an effective gene therapy for prostate cancer: new technologies with potential to translate from the laboratory into the clinic. Discov Med. 11:46–56. 2011.PubMed/NCBI
5	Hu W and Kavanagh JJ: Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 4:721–729. 2003. View Article : Google Scholar : PubMed/NCBI
6	Danen-Van Oorschot AA, Zhang YH, Leliveld SR, Rohn JL, Seelen MC, Bolk MW, Van Zon A, Erkeland SJ, Abrahams JP, Mumberg D and Noteborn MH: Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. J Biol Chem. 278:27729–27736. 2003.PubMed/NCBI
7	Oro C and Jans DA: The tumour specific pro-apoptotic factor apoptin (Vp3) from chicken anaemia virus. Curr Drug Targets. 5:179–190. 2004. View Article : Google Scholar : PubMed/NCBI
8	Poon IK, Oro C, Dias MM, Zhang J and Jans DA: Apoptin nuclear accumulation is modulated by a CRM1-recognized nuclear export signal that is active in normal but not in tumor cells. Cancer Res. 65:7059–7064. 2005. View Article : Google Scholar : PubMed/NCBI
9	Li X, Jin N, Mi Z, Lian H, Sun L and Zheng H: Antitumor effects of a recombinant fowlpox virus expressing Apoptin in vivo and in vitro. Int J Cancer. 119:2948–2957. 2006. View Article : Google Scholar : PubMed/NCBI
10	Maioli E, Torricelli C, Fortino V, Carlucci F, Tommassini V and Pacini A: Critical appraisal of the MTT assay in the presence of rottlerin and uncouplers. Biol Proced Online. 11:227–240. 2009. View Article : Google Scholar : PubMed/NCBI
11	Mitrovic T, Stamenkovic S, Cvetkovic V, Tosic S, Stankovic M, Radojevic I, Stefanovic O, Comic L, Dacic D, Curcic M and Markovic S: Antioxidant, antimicrobial and antiproliferative activities of five lichen species. Int J Mol Sci. 12:5428–5448. 2011. View Article : Google Scholar : PubMed/NCBI
12	Baskic D, Popovic S, Ristic P and Arsenijevic NN: Analysis of cycloheximide-induced apoptosis in human leukocytes: fluorescence microscopy using Annexin V/propidium iodide versus acridin orange/ethidium bromide. Cell Biol Int. 30:924–932. 2006. View Article : Google Scholar
13	Ding W, Ju S, Jiang S, Zhu L, Wang Y and Wang H: Reduced APRIL expression induces cellular senescence via a HSPG-dependent pathway. Pathol Oncol Res. 15:693–701. 2009. View Article : Google Scholar : PubMed/NCBI
14	Candal E, Anadon R, DeGrip WJ and Rodriguez-Moldes I: Patterns of cell proliferation and cell death in the developing retina and optic tectum of the brown trout. Brain Res Dev Brain Res. 154:101–119. 2005. View Article : Google Scholar : PubMed/NCBI
15	Panigrahi S, Stetefeld J, Jangamreddy JR, Mandal S, Mandal SK and Los M: Modeling of molecular interaction between apoptin, BCR-Abl and CrkL - an alternative approach to conventional rational drug design. PLoS One. 7:e283952012. View Article : Google Scholar : PubMed/NCBI
16	Adair BM: Immunopathogenesis of chicken anemia virus infection. Dev Comp Immunol. 24:247–255. 2000. View Article : Google Scholar : PubMed/NCBI
17	Los M, Panigrahi S, Rashedi I, Mandal S, Stetefeld J, Essmann F and Schulze-Osthoff K: Apoptin, a tumor-selective killer. Biochim Biophys Acta. 1793:1335–1342. 2009. View Article : Google Scholar : PubMed/NCBI
18	van der Eb MM, Pietersen AM, Speetjens FM, Kuppen PJ, van de Velde CJ, Noteborn MH and Hoeben RC: Gene therapy with apoptin induces regression of xenografted human hepatomas. Cancer Gene Ther. 9:53–61. 2002.PubMed/NCBI
19	Olijslagers S, Dege AY, Dinsart C, Voorhoeve M, Rommelaere J, Noteborn MH and Cornelis JJ: Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin. Cancer Gene Ther. 8:958–965. 2001. View Article : Google Scholar : PubMed/NCBI
20	Pietersen AM, van der Eb MM, Rademaker HJ, van den Wollenberg DJ, Rabelink MJ, Kuppen PJ, van Dierendonck JH, van Ormondt H, Masman D, van de Velde CJ, van der Eb AJ, Hoeben RC and Noteborn MH: Specific tumor-cell killing with adenovirus vectors containing the apoptin gene. Gene Ther. 6:882–892. 1999. View Article : Google Scholar : PubMed/NCBI
21	Heilman DW, Teodoro JG and Green MR: Apoptin nucleocytoplasmic shuttling is required for cell type-specific localization, apoptosis, and recruitment of the anaphase-promoting complex/cyclosome to PML bodies. J Virol. 80:7535–7545. 2006. View Article : Google Scholar
22	Maddika S, Booy EP, Johar D, Gibson SB, Ghavami S and Los M: Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. J Cell Sci. 118:4485–4493. 2005. View Article : Google Scholar
23	Maddika S, Mendoza FJ, Hauff K, Zamzow CR, Paranjothy T and Los M: Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol Ther. 5:10–19. 2006. View Article : Google Scholar : PubMed/NCBI
24	Maddika S, Wiechec E, Ande SR, Poon IK, Fischer U, Wesselborg S, Jans DA, Schulze-Osthoff K and Los M: Interaction with PI3-kinase contributes to the cytotoxic activity of apoptin. Oncogene. 27:3060–3065. 2008. View Article : Google Scholar : PubMed/NCBI
25	Wagstaff KM and Jans DA: Nuclear drug delivery to target tumour cells. Eur J Pharmacol. 625:174–180. 2009. View Article : Google Scholar : PubMed/NCBI
26	Jiang J, Cole D, Westwood N, Macpherson L, Farzaneh F, Mufti G, Tavassoli M and Gaken J: Crucial roles for protein kinase C isoforms in tumor-specific killing by apoptin. Cancer Res. 70:7242–7252. 2010. View Article : Google Scholar : PubMed/NCBI
27	Los M, Maddika S, Erb B and Schulze-Osthoff K: Switching Akt: from survival signaling to deadly response. Bioessays. 31:492–495. 2009. View Article : Google Scholar : PubMed/NCBI
28	Maddika S, Panigrahi S, Wiechec E, Wesselborg S, Fischer U, Schulze-Osthoff K and Los M: Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin’s anticancer toxicity. Mol Cell Biol. 29:1235–1248. 2009.PubMed/NCBI
29	Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
30	Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG and Au JL: Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res. 63:579–585. 2003.PubMed/NCBI
31	Wirth T, Kuhnel F and Kubicka S: Telomerase-dependent gene therapy. Curr Mol Med. 5:243–251. 2005. View Article : Google Scholar
32	Hernandez-Alcoceba R, Pihalja M, Qian D and Clarke MF: New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther. 13:1737–1750. 2002. View Article : Google Scholar : PubMed/NCBI
33	Kurihara T, Brough DE, Kovesdi I and Kufe DW: Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest. 106:763–771. 2000. View Article : Google Scholar : PubMed/NCBI